REFERENCES
- Rait JL. Seven million too many. Br J Ophthalmol 1996; 80: 385–386.
- Mitchell P, Smith W, Attebo K, Healey PR. The prevalence of open angle glaucoma in Australia. The Blue Mountains Eye Study. Ophthalmology 1996; 103: 1661–1691.
- Quigley HA. The number of people with glaucoma worldwide. Br J Ophthalmol 1996; 80: 389–393.
- Leske MC. The epidemiology of open angle glaucoma: a review. Am J Epidemiol 1983; 118: 166–191.
- Sponsel WE, Ritch R, Stamper R et al. Prevent Blindness America Visual Field Screening Study. The prevent Blindness America Advisory Committee. Am J Ophthalmol 1995; 120: 699–708.
- Hart W, Becker B. The onset and evolution of glaucomatous visual field defects. Ophthalmology 1982; 89: 268–279.
- Araugo SV, Spaeth GL, Roth SM, Starita RJ. A ten year follow up on a prospective, randomised trial of post‐operative corticosteroids after trabeculectomy. Ophthalmology 1995; 102: 1753–1759.
- Drance SM. The collaborative Normal Tension Glaucoma Study and some of its lessons. Can J Ophthalmol 1999; 34: 1–6.
- van Buskirk EM, Weinreb RN, Berry DP et al. Betaxolol in patients with glaucoma and asthma. Am J Ophthalmol 1986; 101: 531–534.
- Osborne NN, Cajevieille C, Carvallo AC et al. in vivo and in vitro experiments show that betaxolol is a retinal neuro‐protective agent. Brain Res 1997; 751: 113–123.
- Watson PG. Latanaprost. Two years' experience of its use in the United Kingdom. Ophthalmology 1998; 105: 82–87.